Neurogene Inc. Insider Trading

NGNE

Last 12 months

Insiders sold $1.13M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Nov 2024.

Net open-market

−$1.13M

0 buys · 9 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Nov 2024

Nov 22, 2024

Get an email when NGNE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 6 – 7	Christine Mikail Cvijic President and CFO	Sold10b5-1 plan 2 parts	4,800	$36.12 average	173K	5.4%	Form 4
Jul 1 – 2	Christine Mikail Cvijic President and CFO	Sold10b5-1 plan 3 parts	4,800	$34.71 average	167K	5.1%	Form 4
May 6	Christine Mikail Cvijic President and CFO	Sold10b5-1 plan 2 parts	9,600	$31.26 average	300K	9.3%	Form 4
Mar 26	Julie Jordan Chief Medical Officer	Sold10b5-1 plan	828	$21.89	18K	6.2%	Form 4
Mar 26	Rachel McMinn Chief Executive Officer	Sold10b5-1 plan	3,352	$22.07	74K	0.2%	Form 4
Mar 26	Christine Mikail Cvijic President and CFO	Sold10b5-1 plan	2,558	$21.62	55K	2.4%	Form 4
Mar 13	Stuart Cobb Chief Scientific Officer	Sold10b5-1 plan 3 parts	6,797	$20.81 average	141K	18%	Form 4
Mar 13	Christine Mikail Cvijic President and CFO	Sold10b5-1 plan 3 parts	4,045	$20.81 average	84K	3.7%	Form 4
Feb 27	Christine Mikail Cvijic President and CFO	Sold10b5-1 plan	4,800	$25.11	121K	4.2%	Form 4
May 14, 2025	Stuart Cobb Chief Scientific Officer	Sold10b5-1 plan	6,797	$15.15	103K	25%	Form 4
Mar 13, 2025	Christine Mikail Cvijic President and CFO	Sold10b5-1 plan	4,501	$16.94	76K	5.9%	Form 4
Nov 26, 2024	Srinivas Akkaraju Large holder	Bought 4 parts	48,770	$25.83 average	$1.26M	2.9%	Form 4
Nov 22, 2024	Christine Mikail Cvijic President and CFO	Bought	24,000	$20.48	492K	45%	Form 4
Nov 22, 2024	Rachel McMinn Chief Executive Officer	Bought	47,500	$20.40	969K	3.8%	Form 4

Jul 6 – 710b5-1 plan
Christine Mikail Cvijic
President and CFO · sold 4,800 at avg $36.12
173K
5.4% of stake
Jul 1 – 210b5-1 plan
Christine Mikail Cvijic
President and CFO · sold 4,800 at avg $34.71
167K
5.1% of stake
May 610b5-1 plan
Christine Mikail Cvijic
President and CFO · sold 9,600 at avg $31.26
300K
9.3% of stake
Mar 2610b5-1 plan
Julie Jordan
Chief Medical Officer · sold 828 at $21.89
18K
6.2% of stake
Mar 2610b5-1 plan
Rachel McMinn
Chief Executive Officer · sold 3,352 at $22.07
74K
0.2% of stake
Mar 2610b5-1 plan
Christine Mikail Cvijic
President and CFO · sold 2,558 at $21.62
55K
2.4% of stake
Mar 1310b5-1 plan
Stuart Cobb
Chief Scientific Officer · sold 6,797 at avg $20.81
141K
18% of stake
Mar 1310b5-1 plan
Christine Mikail Cvijic
President and CFO · sold 4,045 at avg $20.81
84K
3.7% of stake
Feb 2710b5-1 plan
Christine Mikail Cvijic
President and CFO · sold 4,800 at $25.11
121K
4.2% of stake
May 14, 202510b5-1 plan
Stuart Cobb
Chief Scientific Officer · sold 6,797 at $15.15
103K
25% of stake
Mar 13, 202510b5-1 plan
Christine Mikail Cvijic
President and CFO · sold 4,501 at $16.94
76K
5.9% of stake
Nov 26, 2024
Srinivas Akkaraju
Large holder · bought 48,770 at avg $25.83
$1.26M
2.9% of stake
Nov 22, 2024
Christine Mikail Cvijic
President and CFO · bought 24,000 at $20.48
492K
45% of stake
Nov 22, 2024
Rachel McMinn
Chief Executive Officer · bought 47,500 at $20.40
969K
3.8% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NGNE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with NGNE

CompareIntrinsic value

RFLRafael Holdings Inc.

$1.08-3.57%40

STTKShattuck Labs Inc.

$5.56-2.80%40

TERNTerns Pharmaceuticals, Inc.

$0.01+0.00%10

SCNXScienture Holdings Inc.

$3.22-7.74%0

ORGSOrgenesis Inc.

$0.05+0.00%20

MTNBMatinas Biopharma Holdings Inc.

$1.51-20.53%40

IGCIGC Pharma Inc.

$0.19-5.00%26

BTAIBioXcel Therapeutics, Inc.

$0.01-3.60%30

Held by ETFs

NGNE is in 15 US ETFs. The largest of them, with NGNE's weight in each:

Spot a number that looks wrong? Check it in NGNE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NGNE

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.